Handbook of Chronic Myeloid Leukemia
- Publisher's listprice EUR 53.49
-
22 184 Ft (21 128 Ft + 5% VAT)
The price is estimated because at the time of ordering we do not know what conversion rates will apply to HUF / product currency when the book arrives. In case HUF is weaker, the price increases slightly, in case HUF is stronger, the price goes lower slightly.
- Discount 20% (cc. 4 437 Ft off)
- Discounted price 17 748 Ft (16 902 Ft + 5% VAT)
Subcribe now and take benefit of a favourable price.
Subscribe
22 184 Ft
Availability
printed on demand
Why don't you give exact delivery time?
Delivery time is estimated on our previous experiences. We give estimations only, because we order from outside Hungary, and the delivery time mainly depends on how quickly the publisher supplies the book. Faster or slower deliveries both happen, but we do our best to supply as quickly as possible.
Product details:
- Edition number 2014
- Publisher Springer International Publishing
- Date of Publication 26 November 2014
- Number of Volumes 1 pieces, Book
- ISBN 9783319083490
- Binding Paperback
- No. of pages65 pages
- Size 201x127 mm
- Weight 952 g
- Language English
- Illustrations XIII, 65 p. 14 illus., 12 illus. in color. Illustrations, black & white 0
Categories
Long description:
This concise, clinically focused pocket handbook assembles and synthesizes the latest developments and trends in the diagnosis and treatment of CML and provides an authoritative and convenient summary of the latest progress in TKI trials, the molecular monitoring of CML responses, and the development of new therapies to overcome resistance and improve patient care. Chronic myeloid leukemia (CML) is a rare type of leukemia (1–2 per 100,000 people) but is the most common chronic myeloproliferative neoplasm. CML remains a key model for the improved understanding of the pathophysiology of a malignancy at a molecular level; CML was the first cancer to be associated with a recurring chromosome abnormality, which generates the Philadelphia (Ph) chromosome and its associated fusion gene BCR-ABL1. The clinical outcome for patients with CML has changed dramatically in the past 15 years and this has been due to the development of tyrosine kinase inhibitors (TKIs), compounds that inhibit the activity of the oncogenic BCR-ABL1 protein. A number of first-, second- and third-generation TKIs are now available for the treatment of CML, although a number of treatment challenges remain, not least the development of treatment-resistant CML. Parallel to the development of specific drugs for treating CML, major advances have been made in the field of disease monitoring and standardization of response criteria.
MoreTable of Contents:
Epidemiology and risk factors.- Pathophysiology.-Diagnosis.- Management of patients with CML.- Challenges of treatment: treatment-resistant CML.- Useful resources for your patients and caregivers.
More
International Relations Theory for the Twenty-First Century
31 053 HUF
27 948 HUF
